MT1988 · program
MT1988 (tropisetron/varenicline) for Schizophrenia
MT1988, Monument Therapeutics' fixed-dose combination of tropisetron (alpha7 nicotinic partial agonist / 5-HT3 antagonist) and varenicline (alpha4beta2 nicotinic partial agonist), for cognitive impairment associated with schizophrenia (CIAS), intended as add-on to antipsychotics. A Phase 1 multiple-dose safety/PK study in healthy adults (NCT06728176, 42 enrolled, 14-day dosing at four dose levels vs placebo) ran November 2024 to April 2025; Monument reported it was generally well tolerated with no severe or serious adverse events and that results support advancement into Phase 2. The program's first patient study is not in diagnosed schizophrenia but in people at clinical high risk (CHR) for psychosis: NCT07226895 (SCZ201), a Phase 1/2, 8-week, randomised, double-blind, placebo-controlled proof-of-principle study of two MT1988 doses in ~150 participants aged 17-30, run within the FNIH-managed AMP SCZ programme with NIMH as collaborator. Primary endpoints are change at week 8 in verbal memory (PennCNB list learning), attenuated positive symptoms (PSYCHS) and negative symptoms (NSI-PR). First patient dosed March 2026; estimated primary completion September 2027. No efficacy data have been reported.
Development timeline
- UpcomingClinicalTrials.gov estimated primary completion of the Phase 1/2 MT1988 proof-of-principle study in clinical high risk for psychosis (NCT07226895): September 2027.
- Phase 1/2 proof-of-principle study NCT07226895 in participants at clinical high risk for psychosis started (registry actual start 2026-03-03); Monument announced first patient dosed on 2026-03-10.
- metPhase 1 multiple-dose study of MT1988 in healthy adults: generally well tolerated with no severe or serious adverse events; supports advancement into Phase II.↗
- Phase 1 primary completion (actual) per registry; Monument announced positive Phase I results on 2025-06-23 (generally well tolerated, no severe or serious AEs).
- First clinical study of MT1988 started: Phase 1 multiple-dose safety/PK study in healthy adults (NCT06728176, SCZ103) at BDD Pharma; announced 2024-11-26.
Readouts
- September 2027AnticipatedRegistry resultsNCT07226895
ClinicalTrials.gov estimated primary completion of the Phase 1/2 MT1988 proof-of-principle study in clinical high risk for psychosis (NCT07226895): September 2027.
- 2025-06-23ReportedTopline datametNCT06728176
Phase 1 multiple-dose study of MT1988 in healthy adults: generally well tolerated with no severe or serious adverse events; supports advancement into Phase II. ↗
Clinical trials in Schizophrenia
NCT07226895SCZ201Phase 1/2Recruitingn=150
A Study to Explore Changes in Cognitive, Clinical, Biological and Digital Measures Following 8 Weeks of Twice-daily Dosing of MT1988 and to Evaluate Safety & Tolerability of MT1988, in Participants at Clinical High Risk (CHR) for Psychosis
NCT06728176SCZ103Phase 1Completedn=42
A Single Centre, Double Blinded, Randomised, Parallel Arm, Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of MT1988 in Healthy Adults
Formulations
| Formulation | Route | Regimen | Pharmacokinetics |
|---|---|---|---|
| MT1988 oral fixed-dose combination (twice daily) Oral, twice daily. Phase 1 (NCT06728176): four dose levels vs placebo for 14 days in healthy adults. Phase 1/2 (NCT07226895): low dose and high dose vs placebo, twice daily for 8 weeks. Absolute doses of each component are not disclosed. | Oral | Twice daily | — |
Mechanism of action
Dual-component nicotinic strategy. Tropisetron, marketed outside the US as a 5-HT3 receptor antagonist antiemetic, is a potent and selective partial agonist at alpha7 nicotinic acetylcholine receptors, a long-pursued pro-cognitive target in schizophrenia. Varenicline, the approved smoking-cessation drug, is an alpha4beta2 nicotinic receptor partial agonist. Monument's patent frames the combination as addressing positive, negative and cognitive symptoms while mitigating the gastrointestinal side effects that alpha7 agonists have shown in trials, attributed to 5-HT3 activity; Monument describes the combination as designed to remediate a prevalent off-target side effect of nicotinic agonists.
| Target | Action | Affinity |
|---|---|---|
| alpha7 nAChRprimaryCHRNA7 | Partial agonist | —ⓘ |
| 5-HT3 receptorHTR3A | Antagonist | —ⓘ |
| alpha4beta2 nAChRCHRNA4 | Partial agonist | —ⓘ |
← Full MT1988 compound page (identity, identifiers, all indications)
Sources
- Coe JW, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48(10):3474-7 — PubMed
- Macor JE, et al. The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist. Bioorg Med Chem Lett. 2001;11(3):319-21 — PubMed
- Monument Therapeutics Announces First Patient Dosed in Clinical Trial of MT1988 in Patients at Clinical High Risk for Psychosis (2026-03-10) — Monument Therapeutics
- Monument Therapeutics Announces Grant of US Patent for MT1988 (2026-04-30) — Monument Therapeutics
- Monument Therapeutics Announces Partnership with FNIH for Clinical Trial of MT1988 (2025-08-19) — Monument Therapeutics
- Monument Therapeutics Launches First Clinical Study of MT1988 (2024-11-26) — Monument Therapeutics
- Monument Therapeutics Reports Positive Phase I Results for Novel CIAS Treatment (2025-06-23) — Monument Therapeutics
- Monument Therapeutics Secures GBP 1M Investment to Fund its Schizophrenia Programme (2024-10-15) — Monument Therapeutics
- Monument Therapeutics Secures GBP 850k to Advance Schizophrenia Treatment (2025-02-25) — Monument Therapeutics
- NCT06728176 (SCZ103) - Safety and PK of Multiple Doses of MT1988 in Healthy Adults — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT07226895 (SCZ201) - MT1988 in Participants at Clinical High Risk for Psychosis — ClinicalTrials.gov (U.S. National Library of Medicine)